Heather Moore

Breast Oncology Pharmacist at Duke Cancer Institute
Exercise Enthusiast, Animal Lover, Wolfpack Supporter

[Heather Moore @HeatherMoore16]

Getting asked this more frequently as we expand use. Helpful for patients and providers!

[ESMO Open @ESMO_Open]

Scalp cooling outcomes in patients receiving trastuzumab deruxtecan for metastatic breast cancer in @ESMO_Open. No benefit of scalp cooling in terms of hair preservation or quality of life.G2 alopecia primary reason for scalp cooling discontinuation. https://t.co/uKW3G2S6gg

[Paolo Tarantino @PTarantinoMD]

Could an MRI after 12 weeks of neoadjuvant THP predict pCR?

Sub-analysis from CompassHER2pCR (~1400 pts) presented at #ASCO26

👉86% of ER-/HER2+ tumors with rCR on MRI actually had pCR
👉lower accuracy in ER+ disease, with 60% adequately predicted

Provides rationale to start with neoadjuvant THP and escalate with T-DXd if no MRI response among patients with stage II ER-/HER2+ disease

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

Perhaps the most important breast cancer discussion this year at ASCO. A brilliant analysis of PFS2 and its meaning (or lack thereof) in advanced breast cancer. Required viewing for all clinical investigators.

[Erika Hamilton, MD, FASCO @ErikaHamilton9]

#DB05 update on #ILD with T-DXd

10% ILD 🫁 , 2 cases fatal

Radiation pneumonitis ☢️ (RP) incidence ~ 30%

Having ILD did not ⬆️ chance of RP

📌No diff in ILD 🫁 based on sequential or concurrent radiotherapy ☢️

Moderate renal dysfunction ⬆️ risk ILD
#ASCO26

[Komal Jhaveri, MD, FACP, FASCO @jhaveri_komal]

Super timely as FDA approved Dato in 1L metastatic TNBC for those who are not PD-1/PDL-1 I candidates based on the phase 3 TB-02 trial today!

[Paolo Tarantino @PTarantinoMD]

The approval of T-DXd for the (neo)adjuvant treatment of HER2+ breast cancer will add an invaluable tool to our arsenal. Yet, in this era of right-sizing, not all patients require T-DXd treatment to be cured. Some thoughts in my recent JCO editorial. https://t.co/tKCgzzbdiq

[Paolo Tarantino @PTarantinoMD]

BREAKING: positive results from the VIKTORIA-1 PIK3CA-mutant cohort

Both the gedatolisib triplet and doublet improved PFS vs fulv/alpelisib, positioning gedatolisib as an active option irrespective of PIK3CA status. Key caveat: the weekly IV formulation. https://t.co/ZclPhQmcWl

[Heather Moore @HeatherMoore16]

EKG and QTcF at baseline are essential!

[Paolo Tarantino @PTarantinoMD]

⚠️ Important to remember: 10% of patients on vepdegestrant are expected to develop QT prolongation (1.6% G3) — warranting caution in the coadministration of other QT-prolonging drugs

[Paolo Tarantino @PTarantinoMD]

Very hard to interpret OS in SERENA-6, given imbalance in subsequent treatment (most notably, ADC treatment, more common in the control arm).

Yet very important endpoint in light of the testing of a new strategy to treat MBC (i.e. treatment switch prior to anatomic progression).

[Paolo Tarantino @PTarantinoMD]

Results from BioItaLEE published in CCR: with a blood draw after 2 weeks of treatment, you can predict whether a patient will remain on 1L letrozole/ribo for a median of 1 vs ~2 yrs. Congrats @BianchiniGP and colleagues for the publication! 🇮🇹💪 https://t.co/gedniOWEMz

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

The @FDAOncology just posted materials for the ODAC on camizestrant in SERENA-6 trial. Key issue: PFS/PFS2. Should be a very interesting discussion.
https://t.co/rLQkCe6d48

[Aumilto Silva, MD. @aumilto]

New real-world study in early HER2+ and TNBC after neoadjuvant therapy:

In this study pCR remained the strongest prognostic marker. In 863 patients, 3-year RFS was 98% with pCR vs 79% with residual disease; 3-year OS was 100% vs 88%. In HER2+, 3-year RFS was 99% with pCR vs 87% with RD; in TNBC, 97% vs 72%.

Baseline cT/cN/subtype predicted worse outcomes mainly in patients with residual disease. Among patients achieving pCR, baseline stage was not significantly associated with RFS or OS in this cohort.

In this study pCR appears to largely mitigate the adverse effect of initial tumor burden, but residual disease still identifies a clearly higher-risk population needing escalation/novel strategies.
@CCortiMD @stolaney1 @oncodaily

👉 https://t.co/gXjmCHnVjf

[Nancy Lin, MD @nlinmd]

There are so few trials which enroll patients with LMD. So glad to demonstrate benefit with the HER2CLIMB regimen including meaningful improvements in neuro deficits and quality of life. Inclusion ➡️ progress.

[Paolo Tarantino @PTarantinoMD]

Results from the DB08 trial of T-DXd combos for HER2-low MBC out in @CCR_AACR. The most intriguing cohort: T-DXd+anastrozole, with ORR 71% and PFS 13.4 months. The DFCI-led ERADICATE phase 2 trial is ongoing to evaluate T-DXd + elacestrant in this setting. https://t.co/c3CU68cfKK

[Sara Tolaney @stolaney1]

FOURLIGHT-1: Ph II study of fulvestrant + atirmociclib (CDK4 selective inhib) vs fulvestrant or everolimus + exemestane is positive, with HR 0.6. Great news, as this novel CDK4i seems very well tolerated!
@antgiorda
https://t.co/ZWMB0bOKdx

[Oscar Tahuahua @OscarTahuahua]

1 in 5 pts. No symptoms.

In a prospective study (n=112) of HER2+ and TNBC, brain MRI screening detected metastases in 19.6% (9.8% at baseline) and 2/3 were asymptomatic.

Earlier detection may allow more SRS and less WBRT.

Is it time to rethink brain MRI screening?
https://t.co/vJ2vUHXs56 @OncoAlert

[Harold J. Burstein, MD, PhD, FASCO @DrHBurstein]

persevERA oral SERD study (1st line ER+ MBC in combo with palbo) from @Roche reads out negative. Will it prompt reconsideration of oSERDs in ESR1 wt / less resistant populations including adjuvant trials and other CDK46i pairings ?

https://t.co/t78KNxoIl8

[Dr Sarah Sammons @drsarahsam]

Can someone on the guidelines explain why Saci is preferred over Dato-DXd when Dato had a higher ORR and OS benefits…

Crossover differences acknowledged?

[Matteo Lambertini, MD PhD @matteolambe]

One of the most unanswered question in early #BreastCancer: how to extend adjuvant endocrine therapy in premenopausal women after 5y of #LHRHa #OFS…congrats (& thank you) @ValenzaCarmine @AnnPartridgeMD et all !

https://t.co/FJE8guzfJD

@OncoAlert @JCO_ASCO @DanaFarber @ASCO

[Heather Moore @HeatherMoore16]

Great review of practice changing advances over the last 5 years!

[Paolo Tarantino @PTarantinoMD]

When I moved to the US in 2021, breast oncology was very different. With 2025 coming to an end, I decided to look back and review 10 major milestones in BC medical oncology care we saw over the past 5 years. With hope and expectation to see so much more unfolding over the next 5!